{"id":57736,"date":"2026-02-24T17:56:31","date_gmt":"2026-02-24T09:56:31","guid":{"rendered":"https:\/\/flcube.com\/?p=57736"},"modified":"2026-02-24T17:56:32","modified_gmt":"2026-02-24T09:56:32","slug":"harbour-biomed-licenses-hbm4003-to-solstice-oncology-in-1-2b-deal-expands-global-footprint-for-ctla-4-asset","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57736","title":{"rendered":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset"},"content":{"rendered":"\n<p><strong>Harbour BioMed (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG:\u202f2142<\/a>)<\/strong> announced a <strong>licensing agreement and equity partnership<\/strong> with <strong>Solstice Oncology<\/strong>, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice <strong>exclusive development and commercialization rights<\/strong> to <strong>HBM4003<\/strong>, a clinical\u2011stage candidate, in regions <strong>outside Greater China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Harbour BioMed (HKG:\u202f2142)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Solstice Oncology (VC\u2011backed clinical\u2011stage biotech)<\/td><\/tr><tr><td><strong>Licensed Asset<\/strong><\/td><td>HBM4003 (clinical\u2011stage candidate)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive rights outside Greater China<\/td><\/tr><tr><td><strong>Upfront Consideration<\/strong><\/td><td><strong>&gt;\u202fUSD\u202f105\u202fmillion<\/strong><\/td><\/tr><tr><td>\u2014 Cash Upfront<\/td><td>USD\u202f50\u202fmillion<\/td><\/tr><tr><td>\u2014 Near\u2011Term Payments<\/td><td>USD\u202f5\u202fmillion<\/td><\/tr><tr><td>\u2014 Equity Stake<\/td><td>&gt;\u202fUSD\u202f50\u202fmillion in Solstice Oncology<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>USD\u202f1.1\u202fbillion<\/strong> (development, regulatory, commercial)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales outside Greater China<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td><strong>&gt;\u202fUSD\u202f1.2\u202fbillion<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-asset-hbm4003\">Strategic Asset \u2013 HBM4003<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Clinical\u2011stage biologic candidate<\/li>\n\n\n\n<li><strong>Target Mechanism:<\/strong> <strong>CTLA\u20114<\/strong> (cytotoxic T\u2011lymphocyte\u2011associated protein 4) \u2013 immune checkpoint inhibitor pathway<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Harbour BioMed&#8217;s proprietary <strong>heavy chain\u2011only antibody platform<\/strong> enables unique molecular properties<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Clinical\u2011stage with ongoing studies<\/li>\n\n\n\n<li><strong>Global Rights Structure:<\/strong> Harbour BioMed retains Greater China rights; Solstice Oncology gains ex\u2011China control<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion:<\/strong> The <strong>USD\u202f105\u202fmillion+ upfront<\/strong> provides Harbour BioMed with immediate non\u2011dilutive funding to advance its pipeline while retaining Chinese commercial rights.<\/li>\n\n\n\n<li><strong>Equity Upside:<\/strong> The <strong>>\u202fUSD\u202f50\u202fmillion equity stake<\/strong> in Solstice Oncology aligns Harbour BioMed with the licensee&#8217;s future success and potential valuation appreciation.<\/li>\n\n\n\n<li><strong>Milestone Potential:<\/strong> The <strong>USD\u202f1.1\u202fbillion milestone package<\/strong> reflects confidence in HBM4003&#8217;s blockbuster potential across multiple oncology indications.<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Partnering with a <strong>VC\u2011backed U.S. biotech<\/strong> provides Harbour BioMed with a dedicated development partner possessing deep oncology expertise and U.S. market access capabilities.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biotech Out\u2011Licensing Trend:<\/strong> The deal exemplifies the <strong>accelerating global licensing activity<\/strong> by Chinese biotechs, transferring ex\u2011China rights to Western partners while retaining domestic control.<\/li>\n\n\n\n<li><strong>CTLA\u20114 Market Dynamics:<\/strong> HBM4003 enters a competitive landscape including Bristol Myers Squibb&#8217;s <strong>Yervoy<\/strong>, with potential differentiation through Harbour&#8217;s heavy chain\u2011only antibody technology.<\/li>\n\n\n\n<li><strong>Valuation Benchmark:<\/strong> The <strong>>\u202fUSD\u202f1.2\u202fbillion total deal value<\/strong> sets a strong precedent for clinical\u2011stage Chinese assets, signaling continued appetite from U.S. biotech investors and partners.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, regulatory approvals, and commercial expectations for HBM4003. Actual results may differ due to risks including clinical trial outcomes, Solstice&#8217;s funding capacity, and competitive market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[190,916,4618],"class_list":["post-57736","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-harbour-biomed","tag-hkg-2142","tag-solstice-oncology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57736\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset\" \/>\n<meta property=\"og:description\" content=\"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57736\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T09:56:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T09:56:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset\",\"datePublished\":\"2026-02-24T09:56:31+00:00\",\"dateModified\":\"2026-02-24T09:56:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Harbour BioMed\",\"HKG: 2142\",\"Solstice Oncology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57736#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57736\",\"name\":\"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-24T09:56:31+00:00\",\"dateModified\":\"2026-02-24T09:56:32+00:00\",\"description\":\"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57736\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57736#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57736","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset","og_description":"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.","og_url":"https:\/\/flcube.com\/?p=57736","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T09:56:31+00:00","article_modified_time":"2026-02-24T09:56:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57736#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57736"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset","datePublished":"2026-02-24T09:56:31+00:00","dateModified":"2026-02-24T09:56:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57736"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Harbour BioMed","HKG: 2142","Solstice Oncology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57736#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57736","url":"https:\/\/flcube.com\/?p=57736","name":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-24T09:56:31+00:00","dateModified":"2026-02-24T09:56:32+00:00","description":"Harbour BioMed (HKG:\u202f2142) announced a licensing agreement and equity partnership with Solstice Oncology, a clinical\u2011stage biotechnology company backed by leading venture capital firms. The deal grants Solstice exclusive development and commercialization rights to HBM4003, a clinical\u2011stage candidate, in regions outside Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57736#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57736"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57736#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Licenses HBM4003 to Solstice Oncology in $1.2B+ Deal \u2013 Expands Global Footprint for CTLA\u20114 Asset"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57736"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57736\/revisions"}],"predecessor-version":[{"id":57737,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57736\/revisions\/57737"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}